Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080496 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
A Phase 3 study of Bacterial Pneumonia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
- 20
- Study locations
NCT00080496 is a Phase 3 study of Bacterial Pneumonia that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 430 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00080496, a Phase 3 study of Bacterial Pneumonia, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
Conditions Studied
Interventions
- DRUG Tigecycline
- DRUG Imipenem
- DRUG Cilastatin
Study Locations (20)
Arizona
- - Phoenix
- - Phoenix
- - Scottsdale
- - Scottsdale
California
- - Martinez
- - Modesto
- - Modesto
- - National City
Florida
- - Bay Pines
- - Crystal River
- - Gainesville
- - Orlando
Georgia
- - Atlanta
- - Augusta
- - Roswell
Illinois
- - Chicago
- - Springfield
- - Springfield
Louisiana
- - New Orleans
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080496
The ClinicalTrials.gov registry entry for NCT00080496 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Pneumonia appearing as the primary indexed condition, and to 3 interventions - of which Tigecycline is the first listed.
NCT00080496 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00080496 about?
NCT00080496 is a clinical study titled "Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia". To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
What is the current status of trial NCT00080496?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2003-07. Estimated completion is 2006-12.
What conditions does trial NCT00080496 study?
This clinical trial studies the following conditions: Bacterial Pneumonia.
What interventions are being tested in trial NCT00080496?
The interventions under investigation include: Tigecycline (DRUG), Imipenem (DRUG), Cilastatin (DRUG).
Who is sponsoring clinical trial NCT00080496?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080496 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.